Curi Bio Launches the Curiverse™ at MPS 2026: The Industry's First Closed-Loop Ecosystem for Industrial-Scale, Human-Relevant Drug Discovery Jacqueline De RoseJune 1, 2026
Curi Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of NAMs in Neuromuscular Pharmacology Arianna KieserMarch 20, 2026
Curi Bio Launches Asia-Pacific Hub, Delivering Greater Support to its Growing APAC Business Arianna KieserJanuary 12, 2026
Curi Bio Secures $10M Series B to Scale Human-Relevant Preclinical Platforms and Advanced Data Analysis for Drug Discovery Arianna KieserDecember 2, 2025
Curi Bio Celebrates Grand Opening of New Global Headquarters in Seattle Press ReleasesArianna KieserApril 8, 2025
Curi Bio Unlocks Advanced Cardiac Insights with Novoheart Integration Arianna KieserDecember 19, 2024
Muscle disease researchers receive cutting-edge equipment to test new treatments Arianna KieserSeptember 18, 2024
Curi Bio’s Growth Propels Move to Prime Seattle Location to Advance Cutting-Edge Drug Discovery Research Arianna KieserAugust 22, 2024
Curi Bio, Genetox, and DreamCIS Sign MOU for Strategic Collaboration on 3D Neuromuscular Junction Model for Botox Potency Assay Press ReleasesArianna KieserFebruary 22, 2024
Entrada Therapeutics Highlights Mantarray Data at Frontiers in Myogenesis Conference 2023 Arianna KieserNovember 7, 2023
Curi Bio Launches Nautilus™ and Stingray™ Platforms for Advancing Translational Research Press ReleasesArianna KieserSeptember 18, 2023
Curi Bio Awarded Over $4.4M in NIH Grants to Advance Translational Science Press ReleasesArianna KieserAugust 23, 2023
Curi Bio Launches MantaReady™ iPSC-Derived Skeletal Muscle Myoblasts Press ReleasesArianna KieserJune 6, 2023
[JoVE Video] Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues Arianna KieserMay 4, 2023
Curi Bio Names Nicholas Geisse, Ph.D., as New Chief Executive Officer Curi Bio Names Nicholas A. Geisse, Ph.D., as New Chief Executive Officer Read More Press ReleasesArianna KieserFebruary 14, 2023